Standard BioTools (LAB) Competitors $1.27 +0.07 (+5.83%) Closing price 04:00 PM EasternExtended Trading$1.25 -0.02 (-1.50%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LAB vs. TXG, EYPT, TRNS, ALNT, AEHR, CTKB, SENS, FEIM, MASS, and QSIShould you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include 10x Genomics (TXG), Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Allient (ALNT), Aehr Test Systems (AEHR), Cytek Biosciences (CTKB), Senseonics (SENS), Frequency Electronics (FEIM), 908 Devices (MASS), and Quantum-Si (QSI). These companies are all part of the "measuring and control equipment" industry. Standard BioTools vs. Its Competitors 10x Genomics Eyepoint Pharmaceuticals Transcat Allient Aehr Test Systems Cytek Biosciences Senseonics Frequency Electronics 908 Devices Quantum-Si Standard BioTools (NASDAQ:LAB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership. Which has preferable valuation & earnings, LAB or TXG? Standard BioTools has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStandard BioTools$174.43M2.78-$138.88M-$0.32-3.9710x Genomics$610.78M2.91-$182.63M-$0.70-20.43 Do analysts recommend LAB or TXG? Standard BioTools currently has a consensus target price of $1.55, suggesting a potential upside of 22.05%. 10x Genomics has a consensus target price of $13.54, suggesting a potential downside of 5.30%. Given Standard BioTools' higher probable upside, equities analysts clearly believe Standard BioTools is more favorable than 10x Genomics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Standard BioTools 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.0010x Genomics 1 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.38 Do institutionals & insiders hold more shares of LAB or TXG? 53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 23.2% of Standard BioTools shares are owned by insiders. Comparatively, 9.4% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is LAB or TXG more profitable? 10x Genomics has a net margin of -13.13% compared to Standard BioTools' net margin of -69.08%. 10x Genomics' return on equity of -12.88% beat Standard BioTools' return on equity.Company Net Margins Return on Equity Return on Assets Standard BioTools-69.08% -20.23% -15.32% 10x Genomics -13.13%-12.88%-10.03% Does the media refer more to LAB or TXG? In the previous week, 10x Genomics had 2 more articles in the media than Standard BioTools. MarketBeat recorded 11 mentions for 10x Genomics and 9 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.19 beat 10x Genomics' score of 0.61 indicating that Standard BioTools is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 3 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, LAB or TXG? Standard BioTools has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Summary10x Genomics beats Standard BioTools on 10 of the 15 factors compared between the two stocks. Get Standard BioTools News Delivered to You Automatically Sign up to receive the latest news and ratings for LAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LAB vs. The Competition Export to ExcelMetricStandard BioToolsMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$458.39M$2.08B$5.76B$9.59BDividend YieldN/AN/A4.41%4.09%P/E RatioN/A17.8522.4021.92Price / Sales2.7810.23472.14121.31Price / CashN/A51.9937.7358.48Price / Book1.146.709.536.61Net Income-$138.88M-$63.67M$3.26B$265.56M7 Day Performance3.25%4.61%2.11%1.98%1 Month Performance-6.62%3.25%5.12%1.33%1 Year Performance-34.87%27.99%31.25%21.15% Standard BioTools Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LABStandard BioTools2.5672 of 5 stars$1.27+5.8%$1.55+22.0%-38.1%$458.39M$174.43M0.00620Positive NewsTXG10x Genomics3.7881 of 5 stars$13.46+0.7%$13.54+0.6%-43.1%$1.66B$610.78M-19.231,240EYPTEyepoint Pharmaceuticals1.9403 of 5 stars$11.33+2.2%$25.38+124.0%+28.2%$764.41M$43.27M-4.23120Positive NewsTRNSTranscat2.878 of 5 stars$82.24+0.9%$112.20+36.4%-29.7%$759.88M$288.14M57.511,245Positive NewsAnalyst ForecastALNTAllient3.2267 of 5 stars$44.56+2.4%$35.00-21.5%+110.0%$737.53M$529.97M51.812,525News CoverageAnalyst RevisionAEHRAehr Test Systems1.9169 of 5 stars$19.39+5.9%N/A+22.0%$547.74M$58.97M-149.1490Positive NewsOptions VolumeCTKBCytek Biosciences3.597 of 5 stars$4.06+1.2%$5.60+37.9%-25.5%$510.17M$200.45M-81.20500SENSSenseonics2.3638 of 5 stars$0.47-0.7%$1.55+230.1%+6.2%$382.49M$25.47M-3.6190News CoveragePositive NewsFEIMFrequency Electronics1.3926 of 5 stars$28.38-7.8%N/A+110.5%$299.33M$69.81M11.49200MASS908 Devices2.7489 of 5 stars$6.27-5.4%$8.00+27.6%+42.7%$237.76M$59.63M-11.6160QSIQuantum-Si2.468 of 5 stars$1.09-0.9%$3.48+218.8%+9.9%$222.74M$3.06M-1.60150 Related Companies and Tools Related Companies 10x Genomics Alternatives Eyepoint Pharmaceuticals Alternatives Transcat Alternatives Allient Alternatives Aehr Test Systems Alternatives Cytek Biosciences Alternatives Senseonics Alternatives Frequency Electronics Alternatives 908 Devices Alternatives Quantum-Si Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LAB) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Standard BioTools With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access